ID | 57485 |
フルテキストURL |
si_002.csv
614 Bytes
|
著者 |
Yamada, Shoya
Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kawasaki, Mayu
Fujihara, Michiko
Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Watanabe, Masaki
Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Takamura, Yuta
Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Takioku, Maho
Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Nishioka, Hiromi
Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
publons
researchmap
Takeuchi, Yasuo
Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
Makishima, Makoto
Division of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine
Motoyama, Tomoharu
Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka
Ito, Sohei
Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka
Tokiwa, Hiroaki
Department of Chemistry and Research Center of Smart Molecules, Rikkyo University
Nakano, Shogo
Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka
Kakuta, Hiroki
Division of Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
|
抄録 | Ligands for retinoid X receptors (RXRs), "rexinoids", are attracting interest as candidates for therapy of type 2 diabetes and Alzheimer's and Parkinson's diseases. However, current screening methods for rexinoids are slow and require special apparatus or facilities. Here, we created 7-hydroxy-2-oxo-6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2H-chromene-3-carboxylic acid (10, CU-6PMN) as a new fluorescent RXR agonist and developed a screening system of rexinoids using 10. Compound 10 was designed based on the fact that umbelliferone emits strong fluorescence in a hydrophilic environment, but the fluorescence intensity decreases in hydrophobic environments such as the interior of proteins. The developed assay using 10 enabled screening of rexinoids to be performed easily within a few hours by monitoring changes of fluorescence intensity with widely available fluorescence microplate readers, without the need for processes such as filtration.
|
備考 | This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Medicinal Chemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acs.jmedchem.9b00995.
|
発行日 | 2019-09-04
|
出版物タイトル |
Journal of Medicinal Chemistry
|
巻 | 62巻
|
号 | 19号
|
出版者 | American Chemical Society
|
開始ページ | 8809
|
終了ページ | 8818
|
ISSN | 00222623
|
NCID | AA00702411
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2019 American Chemical Society
|
論文のバージョン | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1021/acs.jmedchem.9b00995
|
Citation | J. Med. Chem. 2019, 62, 19, 8809-8818 Publication Date:September 4, 2019 https://doi.org/10.1021/acs.jmedchem.9b00995
|
助成機関名 |
日本学術振興会
|
助成番号 | 12J06716
16K18688
17K06931
18K14391
|